Evonik expands lipid-based drug delivery capabilities with new GMP manufacturing facility in Vancouver

New GMP (good manufacturing practice) facility to meet increasing demand for lipid nanoparticle (LNP) development and clinical drug product manufacturing Evonik invests over 150 million CAD (93 million EUR) Project is supported with up to 68 million CAD (42 million EUR) external funding...